Helius Medical Technologies Announces OTCQB Listing

NEWTOWN, Pa.--()--Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) (“Helius" or the "Company”) is pleased to announce that its common shares have commenced trading on the OTCQB marketplace in the US, under the symbol HSDT.

Euro Pacific Capital, Inc. is qualified Principal American Liaison and has submitted a Letter of Introduction for Helius. Euro Pacific Inc. also serves as market maker on the OTCQB. Principal American Liaisons are responsible for providing professional guidance on OTCQB requirements and US securities laws. As Helius’ market maker, Euro Pacific Capital will provide two-way quotations for the OTCQB listing.

“We are pleased to join the OTCQB marketplace. The commencement of trading on the OTCQB will make the Company’s common stock more accessible to a wider range of investors and reflects the beginning of our plan to allow greater accessibility to Helius' expanding US shareholder base,” said Philippe Deschamps, Chief Executive Officer of Helius.

Helius will continue to trade on the Canadian Stock Exchange under its existing symbol HSM.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance of the PoNS™ device. For more information, please visit www.heliusmedical.com.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Safe Harbor Statement

All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.

Contacts

For Helius Medical Technologies, Inc.
Corporate:
Phil Deschamps, 614-596-2597
pdeschamps@heliusmedical.com
or
US Investor Relations:
Todd James, 646-378-2926
tjames@troutgroup.com
or
Canadian Investor Relations:
778-588-7144
info@heliusmedical.com
or
Media:
Becky Kern, 914-772-2310
bkern@heliusmedical.com

Release Summary

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES OTCQB LISTING

Contacts

For Helius Medical Technologies, Inc.
Corporate:
Phil Deschamps, 614-596-2597
pdeschamps@heliusmedical.com
or
US Investor Relations:
Todd James, 646-378-2926
tjames@troutgroup.com
or
Canadian Investor Relations:
778-588-7144
info@heliusmedical.com
or
Media:
Becky Kern, 914-772-2310
bkern@heliusmedical.com